During the extended duration of treatment, two patients experienced a deterioration in their conditions of schizophrenia and depression; however, the overall results showed that patients’ psychiatric conditions remained stable during treatment with VMAT2 inhibitors. This evidence concerns the gene SLC18A2 and schizophrenia.